Search

Displaying results 4551 - 4560 of 6949 in total
  1. Drug

    Canvuparatide

    go.drugbank.com/drugs/DB18658
    Investigational

    Canvuparatide is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.[L48365]

  2. Drug

    Ivonescimab

    go.drugbank.com/drugs/DB18931
    Investigational

    Ivonescimab is under investigation in clinical trial NCT05184712 (Phase 3 Clinical Study of AK112 for NSCLC Patients).

  3. Drug

    Lactide, L-

    go.drugbank.com/drugs/DB19115
    Investigational

    Lactide, L- is under investigation in clinical trial NCT05450471 (Effectiveness of Endonasal Polymeric Implant for Chronic Rhinosinusitis).

  4. Drug

    NSI-189

    go.drugbank.com/drugs/DB16230
    Investigational

    NSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder).

  5. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  6. Drug

    Chlorophetanol

    go.drugbank.com/drugs/DB11368
    Experimental

    Chlorophetanol is an agent known to have antifungal activities.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  7. Drug

    Oxybuprocaine

    go.drugbank.com/drugs/DB00892
    ApprovedInvestigational

    Oxybuprocaine (also known as Benoxinate) is a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its perm...

    Categories: Anesthetics for Topical Use
  8. Drug

    Abetimus

    go.drugbank.com/drugs/DB06662
    Investigational

    Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

  9. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It...

    Categories: Serotonin Receptor Agonists, Serotonin 5-HT2 Receptor Agonists
  10. Drug

    Lexibulin

    go.drugbank.com/drugs/DB05147
    Investigational

    CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias.